Q1 Earnings Forecast for AVTX Issued By HC Wainwright

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Avalo Therapeutics in a research report issued to clients and investors on Thursday, March 20th. HC Wainwright analyst E. White expects that the company will earn ($1.06) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($19.07) per share. HC Wainwright also issued estimates for Avalo Therapeutics’ Q2 2025 earnings at ($1.09) EPS and Q3 2025 earnings at ($1.13) EPS.

A number of other research analysts have also recently issued reports on AVTX. Piper Sandler started coverage on shares of Avalo Therapeutics in a research report on Friday, February 28th. They set an “overweight” rating and a $48.00 price target for the company. Wedbush reiterated an “outperform” rating and set a $18.00 target price on shares of Avalo Therapeutics in a report on Thursday. Finally, BTIG Research began coverage on Avalo Therapeutics in a research report on Thursday, December 19th. They issued a “buy” rating and a $40.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $35.33.

Avalo Therapeutics Stock Performance

Shares of AVTX stock opened at $7.66 on Monday. The company’s fifty day moving average price is $7.45 and its 200-day moving average price is $9.13. Avalo Therapeutics has a 12 month low of $4.60 and a 12 month high of $34.46.

Institutional Trading of Avalo Therapeutics

Several institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC lifted its stake in shares of Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after buying an additional 3,754 shares in the last quarter. Marshall Wace LLP purchased a new position in Avalo Therapeutics in the 4th quarter worth approximately $114,000. Walleye Capital LLC bought a new position in Avalo Therapeutics in the 4th quarter valued at approximately $145,000. Northern Trust Corp purchased a new stake in Avalo Therapeutics during the 4th quarter valued at $168,000. Finally, Bank of Montreal Can bought a new stake in shares of Avalo Therapeutics in the 4th quarter worth $446,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.